1. RE-CIRCUIT
Trial design: Patients with atrial fibrillation undergoing catheter ablation were randomized to uninterrupted dabigatran 150 mg twice daily (n = 339) versus uninterrupted warfarin with international normalized ratio (INR) 2-3 (n = 339).
(p < 0.001)
Results
Major bleeding: 1.6% of the dabigatran group versus 6.9% of the warfarin group (p < 0.001)
Stroke or transient ischemic attack (TIA): 0 with dabigatran vs. 1 (TIA) with warfarin
Serious adverse event: 3.3% with dabigatran vs. 6.2% with warfarin
6.9 %
Conclusions
1.6
Among patients with atrial fibrillation undergoing catheter ablation, uninterrupted dabigatran was superior to uninterrupted warfarin
Uninterrupted dabigatran was associated with fewer major bleeds (pericardial effusion and groin hematoma) compared with uninterrupted warfarin
Dabigatran
Warfarin
Calkins H, et al. N Engl J Med 2017;376: